Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cancers arise from multiple acquired mutations, which presumably occur over many years. Early stages in cancer development might be present years before cancers become clinically apparent. METHODS: We analyzed data from whole-exome sequencing of DNA in peripheral-blood cells from 12,380 persons, unselected for cancer or hematologic phenotypes. We identified somatic mutations on the basis of unusual allelic fractions. We used data from Swedish national patient registers to follow health outcomes for 2 to 7 years after DNA sampling. RESULTS: Clonal hematopoiesis with somatic mutations was observed in 10% of persons older than 65 years of age but in only 1% of those younger than 50 years of age. Detectable clonal expansions most frequently involved somatic mutations in three genes (DNMT3A, ASXL1, and TET2) that have previously been implicated in hematologic cancers. Clonal hematopoiesis was a strong risk factor for subsequent hematologic cancer (hazard ratio, 12.9; 95% confidence interval, 5.8 to 28.7). Approximately 42% of hematologic cancers in this cohort arose in persons who had clonality at the time of DNA sampling, more than 6 months before a first diagnosis of cancer. Analysis of bone marrow-biopsy specimens obtained from two patients at the time of diagnosis of acute myeloid leukemia revealed that their cancers arose from the earlier clones. CONCLUSIONS: Clonal hematopoiesis with somatic mutations is readily detected by means of DNA sequencing, is increasingly common as people age, and is associated with increased risks of hematologic cancer and death. A subset of the genes that are mutated in patients with myeloid cancers is frequently mutated in apparently healthy persons; these mutations may represent characteristic early events in the development of hematologic cancers. (Funded by the National Human Genome Research Institute and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clonal expansion of blood cells, called clonal hematopoiesis (CH), increases in prevalence with age and is associated with increased risk of hematologic malignancies, but also unexpectedly with increased risk of cardiovascular disease20,21, likely through inflammatory effects of mutant cells22.”
From Somatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states (2026) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This state of abnormal HSC expansion without overt hematologic disease is known as clonal hematopoiesis (CH), and is associated with increased risk of cardiovascular events and blood cancers (3)(4)(5).”
From Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21 (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CHIP carriers have an about 13-fold increased risk of developing myeloid hematological malignancies and an increased risk of all-cause mortality, largely due to cardiovascular disease and stroke.1, 2, 3, 4”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Loss-of-function heterozygous mutations in epigenetic regulators DNMT3A (cytosine methyltransferase) and TET2 (methylcytosine dioxygenase) are the most frequently detected mutations in CHIP, accounting for about 50% to 60% and 10% to 30% of mutations found in CHIP carriers, respectively.1, 2, 3,7,8”
From Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling (2023) · cites this paper as [1]
Experimental — accuracy not yet measured
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 15×
“Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis.”
BackgroundInfluentialDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Genome-wide association analysis identifies 13 new risk loci for schizophrenia
Multicenter Genetic Studies of Schizophrenia Consortium, Ripke, S., Psychosis Endophenotypes International Consortium, Wellcome Trust Case Control Consortium 2, O'Dushlaine, C., Chambert, K., Moran, J. L., Kähler, A. K., Akterin, S., Bergen, S. E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2742 · Cited by 1,496
Self-citation
Cited by
Items 201–300 of 1,031
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia
Churpek, J. E., Pyrtel, K., Kanchi, K.-L., Shao, J., Koboldt, D., Miller, C. A., Shen, D., Fulton, R., O’Laughlin, M., Fronick, C., et al. (2015) · Blood · doi:10.1182/blood-2015-04-641100 · Cited by 216
“Although the presence of clonal hematopoiesis has been associated with elevated risk of leukemic transformation, the absolute riskappears tobe small.(35,36)Wedetectedclonal hematopoiesis in 67% of asymptomatic RUNX1 carriers under the age of 50 years, representing a cumulative risk of 81% by age 50 years.”
BackgroundCancers make their own luck: theories of cancer origins
Jassim, A., Rahrmann, E. P., Simons, B. D., & Gilbertson, R. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00602-5 · Cited by 221
“Recent studies of >200,000 UK Biobank participants has enabled the mapping of inherited predisposition to clonal haematopoiesis — the clonal expansion of a blood stem cell and its progeny driven by somatic driver mutations 109,110 .”
BackgroundAdelman, E. R., Huang, H.-T., Roisman, A., Olsson, A., Colaprico, A., Qin, T., Lindsley, R. C., Bejar, R., Salomonis, N., Grimes, H. L., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1474 · Cited by 221
“PLoS 1069 biology 2007;5(8):e201 doi 10.”
BackgroundInfluentialSallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Duncavage, E. J., Bagg, A., Hasserjian, R. P., DiNardo, C. D., Godley, L. A., Iacobucci, I., Jaiswal, S., Malcovati, L., Vannucchi, A. M., Patel, K. P., et al. (2022) · Blood · doi:10.1182/blood.2022015853 · Cited by 217
An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis
Abegunde, S. O., Buckstein, R., Wells, R. A., & Rauh, M. J. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2017.11.002 · Cited by 230
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Carter, J. L., Hege, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 218
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy
Xu, Y.-P., Lv, L., Liu, Y., Smith, M. D., Li, W.-C., Tan, X.-M., Cheng, M., Li, Z., Bovino, M., Aubé, J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129317 · Cited by 228
Pascual-Figal, D. A., Bayes-Genis, A., Díez-Díez, M., Hernández-Vicente, Á., Vázquez-Andrés, D., de la Barrera, J., Vazquez, E., Quintas, A., Zuriaga, M. A., Asensio-López, M. C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.028 · Cited by 221
Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1486 · Cited by 228
“, DNMT3A, TET2, and PPM1D), as reported in the previous studies (25, 26).”
ResultMerker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0901-sa · Cited by 220
Clonal haematopoiesis and risk of chronic liver disease
Wong, W. J., Emdin, C., Bick, A. G., Zekavat, S. M., Niroula, A., Pirruccello, J. P., Dichtel, L., Griffin, G., Uddin, M. M., Gibson, C. J., et al. (2023) · Nature · doi:10.1038/s41586-023-05857-4 · Cited by 220
Self-citationEpigenetic ageing clocks: statistical methods and emerging computational challenges
Teschendorff, A. E., & Horvath, S. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-024-00807-w · Cited by 197
“In the context of blood tissue, such DNAm outliers, also called stochastic epimutations, increase with age 102 and likely reflect genetic clonal mosaicism, which has independently been shown to increase with age and to be predictive of cancer risk 103–105 .”
Kahn, J. D., Miller, P. G., Silver, A. J., Sellar, R. S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850339 · Cited by 225
Merlevede, J., Droin, N., Qin, T., Meldi, K., Yoshida, K., Morabito, M., Chautard, E., Auboeuf, D., Fenaux, P., Braun, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms10767 · Cited by 219
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 222
Biological and clinical consequences of NPM1 mutations in AML
Heath, E. M., Chan, S. M., Minden, M. D., Murphy, T., Shlush, L. I., & Schimmer, A. D. (2017) · Leukemia · doi:10.1038/leu.2017.30 · Cited by 209
Campia, U., Moslehi, J. J., Amiri-Kordestani, L., Barac, A., Beckman, J. A., Chism, D. D., Cohen, P., Groarke, J. D., Herrmann, J., Reilly, C. M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000641 · Cited by 217
Somatic genomic changes in single Alzheimer’s disease neurons
Miller, M. B., Huang, A. Y., Kim, J., Zhou, Z., Kirkham, S. L., Maury, E. A., Ziegenfuss, J. S., Reed, H. C., Neil, J. E., Rento, L., et al. (2022) · Nature · doi:10.1038/s41586-022-04640-1 · Cited by 223
Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation
Frick, M., Chan, W., Arends, C. M., Hablesreiter, R., Halik, A., Heuser, M., Michonneau, D., Blau, O., Hoyer, K., Christen, F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2184 · Cited by 223
CpG island hypermethylation mediated by DNMT3A is a consequence of AML progression
Spencer, D. H., Russler-Germain, D. A., Ketkar, S., Helton, N. M., Lamprecht, T. L., Fulton, R. S., Fronick, C. C., O’Laughlin, M., Heath, S. E., Shinawi, M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.01.021 · Cited by 219
“In addition, although substantial evidence suggests that DNMT3A mutations occur early in leukemia development (Genovese et al., 2014; Jaiswal et al., 2014; Shlush et al., 2014; Xie et al., 2014), it is not yet clear whether they cause methylation changes in pre-leukemic cells.”
Aging and the rise of somatic cancer-associated mutations in normal tissues
Risques, R. A., & Kennedy, S. R. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007108 · Cited by 216
Spatial biology of cancer evolution
Seferbekova, Z., Lomakin, A., Yates, L. R., & Gerstung, M. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00553-x · Cited by 203
Clonal Hematopoiesis Is Associated With Higher Risk of Stroke
Bhattacharya, R., Zekavat, S. M., Haessler, J., Fornage, M., Raffield, L., Uddin, M. M., Bick, A. G., Niroula, A., Yu, B., Gibson, C., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.037388 · Cited by 222
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Cordua, S., Kjaer, L., Skov, V., Pallisgaard, N., Hasselbalch, H. C., & Ellervik, C. (2019) · Blood · doi:10.1182/blood.2019001113 · Cited by 212
Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., de Philippis, C., Maura, F., Sathiaseelan, V., Tai, Y.-T., Mudie, L., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0037-9 · Cited by 196
Monogenic and polygenic inheritance become instruments for clonal selection
Loh, P.-R., Genovese, G., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2430-6 · Cited by 228
“While read depths were generally insufficient to make a confident assessment on a per-variant level (and making this determination is complicated by mapping bias toward the reference allele [4]), the allelic depths broadly indicated that all or most variants implicated at our seven inherited risk loci were indeed inhe…”
BackgroundInfluentialSelf-citationTesi, B., Davidsson, J., Voss, M., Rahikkala, E., Holmes, T. D., Chiang, S. C. C., Komulainen-Ebrahim, J., Gorcenco, S., Rundberg Nilsson, A., Ripperger, T., et al. (2017) · Blood · doi:10.1182/blood-2016-10-743302 · Cited by 207
Volckmar, A., Sültmann, H., Riediger, A., Fioretos, T., Schirmacher, P., Endris, V., Stenzinger, A., & Dietz, S. (2018) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22517 · Cited by 207
Rare-variant collapsing analyses for complex traits: guidelines and applications
Povysil, G., Petrovski, S., Hostyk, J., Aggarwal, V., Allen, A. S., & Goldstein, D. B. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0177-4 · Cited by 215
Cabagnols, X., Favale, F., Pasquier, F., Messaoudi, K., Defour, J. P., Ianotto, J. C., Marzac, C., Le Couédic, J. P., Droin, N., Chachoua, I., et al. (2016) · Blood · doi:10.1182/blood-2015-07-661983 · Cited by 197
Understanding intrinsic hematopoietic stem cell aging
Mejia-Ramirez, E., & Florian, M. C. (2020) · Haematologica · doi:10.3324/haematol.2018.211342 · Cited by 186
Van Egeren, D., Escabi, J., Nguyen, M., Liu, S., Reilly, C. R., Patel, S., Kamaz, B., Kalyva, M., DeAngelo, D. J., Galinsky, I., et al. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.02.001 · Cited by 206
Exonic Mosaic Mutations Contribute Risk for Autism Spectrum Disorder
Krupp, D. R., Barnard, R. A., Duffourd, Y., Evans, S. A., Mulqueen, R. M., Bernier, R., Rivière, J.-B., Fombonne, E., & O’Roak, B. J. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.07.016 · Cited by 204
Fuster, J. J., Zuriaga, M. A., Zorita, V., MacLauchlan, S., Polackal, M. N., Viana-Huete, V., Ferrer-Pérez, A., Matesanz, N., Herrero-Cervera, A., Sano, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108326 · Cited by 204
“…with aging, which sometimes confer a competitive advantage to the mutant cell, leading to its clonal expansion in the stem cell population and its leukocyte progeny (Buscarlet et al., 2017; Fuster and Walsh, 2018; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014; Zink et al., 2017).”
Clonal hematopoiesis in acquired aplastic anemia
Ogawa, S. (2016) · Blood · doi:10.1182/blood-2016-01-636381 · Cited by 202
“4).(19,20,43,44) Busque et al reported TET2 mutations in PNMs (not in lymphoid cells) from 10 of 182 (5.”
BackgroundInfluentialLarge-Scale Clonal Analysis Resolves Aging of the Mouse Hematopoietic Stem Cell Compartment
Yamamoto, R., Wilkinson, A. C., Ooehara, J., Lan, X., Lai, C.-Y., Nakauchi, Y., Pritchard, J. K., & Nakauchi, H. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.03.013 · Cited by 202
“…of certain somatically acquired clonal mutations in human PB, has recently been strongly correlated with age and is now considered to be a precursor (or ‘‘pre-leukemic’’) state to hematological malignancies (Genovese et al., 2014; Jaiswal et al., 2014; Jan et al., 2012; Shlush et al., 2014).”
Pan, W., Zhu, S., Qu, K., Meeth, K., Cheng, J., He, K., Ma, H., Liao, Y., Wen, X., Roden, C., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.020 · Cited by 198
“It is often mutated somatically in hematopoietic cells in healthy individuals, as well as in patients with myeloid malignancies or solid tumors (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Xie et al., 2014).”
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
Wong, T. N., Miller, C. A., Jotte, M. R. M., Bagegni, N., Baty, J. D., Schmidt, A. P., Cashen, A. F., Duncavage, E. J., Helton, N. M., Fiala, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02858-0 · Cited by 197
Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection
Zekavat, S. M., Lin, S.-H., Bick, A. G., Liu, A., Paruchuri, K., Wang, C., Uddin, M. M., Ye, Y., Yu, Z., Liu, X., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01371-0 · Cited by 198
Self-citationSánchez-Herrero, E., Serna-Blasco, R., Robado de Lope, L., González-Rumayor, V., Romero, A., & Provencio, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943253 · Cited by 184
“It is more frequent in aged patients and patients with solid tumors and of course, it is more likely to be detected with deeper sequencing approaches (120).”
BackgroundClark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.05.004 · Cited by 200
Caye, A., Strullu, M., Guidez, F., Cassinat, B., Gazal, S., Fenneteau, O., Lainey, E., Nouri, K., Nakhaei-Rad, S., Dvorsky, R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3420 · Cited by 189
Identification of Circulating Tumor DNA for the Early Detection of Small-cell Lung Cancer
Fernandez-Cuesta, L., Perdomo, S., Avogbe, P. H., Leblay, N., Delhomme, T. M., Gaborieau, V., Abedi-Ardekani, B., Chanudet, E., Olivier, M., Zaridze, D., et al. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.06.032 · Cited by 193
“In addition, several studies have shown that a subset of normal individuals could undergo clonal hematopoiesis with mutations in driver genes (Genovese et al., 2014; Jacobs et al., 2012; Jaiswal et al., 2014; Laurie et al., 2012; Wong et al., 2015; Xie et al., 2014).”
BackgroundValent, P., Orazi, A., Steensma, D. P., Ebert, B. L., Haase, D., Malcovati, L., van de Loosdrecht, A. A., Haferlach, T., Westers, T. M., Wells, D. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19008 · Cited by 194
“As a result, somatic mutations that are otherwise typically found in MDS or other BM neoplasms, are detected in a subset of healthy individuals, and the prevalence of such clones increases with age [13-15, 33].”
BackgroundInfluentialDysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis
Yamashita, M., Dellorusso, P. V., Olson, O. C., & Passegué, E. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0260-3 · Cited by 179
Kennedy, A. L., Myers, K. C., Bowman, J., Gibson, C. J., Camarda, N. D., Furutani, E., Muscato, G. M., Klein, R. H., Ballotti, K., Liu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21588-4 · Cited by 188
Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis
Arends, C. M., Galan-Sousa, J., Hoyer, K., Chan, W., Jäger, M., Yoshida, K., Seemann, R., Noerenberg, D., Waldhueter, N., Fleischer-Notter, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0047-7 · Cited by 194
“The mutational spectrum detected in our targeted sequencing analyses is in line with previous publications [2, 3, 39], with epigenetic modifiers (DNMT3A, TET2, and ASXL1), spliceosomal components (SF3B1), and genes associated with DNA repair (PPM1D, TP53) being most frequently mutated.”
ResultClinical consequences of clonal hematopoiesis of indeterminate potential
Steensma, D. P. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020222 · Cited by 190
“They found that mutations in known leukemia-driver genes, such as DNMT3A, TET2, and ASXL1, were common even though study subjects’ blood counts were typically normal or only mildly perturbed (eg, increased red cell distribution width).(10,11,20) The prevalence of these mutations increased with aging.”
BackgroundResistance to inflammation underlies enhanced fitness in clonal hematopoiesis
Avagyan, S., Henninger, J. E., Mannherz, W. P., Mistry, M., Yoon, J., Yang, S., Weber, M. C., Moore, J. L., & Zon, L. I. (2021) · Science · doi:10.1126/science.aba9304 · Cited by 192
Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
Chin, R.-I., Chen, K., Usmani, A., Chua, C., Harris, P. K., Binkley, M. S., Azad, T. D., Dudley, J. C., & Chaudhuri, A. A. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00390-5 · Cited by 191
Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
Chan, H. T., Chin, Y. M., Nakamura, Y., & Low, S.-K. (2020) · Cancers · doi:10.3390/cancers12082277 · Cited by 183
“The mutations in these two driver genes are often absent before the development of AML [5,50,65].”
BackgroundMethodResultInfluentialClinical consequences of clonal hematopoiesis of indeterminate potential
Steensma, D. P. (2018) · Hematology · doi:10.1182/asheducation-2018.1.264 · Cited by 188
“They found that mutations in known leukemia-driver genes, such as DNMT3A, TET2, and ASXL1, were common even though study subjects’ blood counts were typically normal or only mildly perturbed (eg, increased red cell distribution width).(10,11,20) The prevalence of these mutations increased with aging.”
BackgroundInnate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS
Trowbridge, J. J., & Starczynowski, D. T. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201544 · Cited by 189
The road ahead in genetics and genomics
McGuire, A. L., Gabriel, S., Tishkoff, S. A., Wonkam, A., Chakravarti, A., Furlong, E. E. M., Treutlein, B., Meissner, A., Chang, H. Y., López-Bigas, N., et al. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0272-6 · Cited by 188
Self-citationde Boer, R. A., Hulot, J.-S., Tocchetti, C. G., Aboumsallem, J. P., Ameri, P., Anker, S. D., Bauersachs, J., Bertero, E., Coats, A. J. S., Čelutkienė, J., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2029 · Cited by 183
Myeloproliferative neoplasm stem cells
Mead, A. J., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2016-10-696005 · Cited by 169
Brunetti, L., Gundry, M. C., & Goodell, M. A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030320 · Cited by 186
“Recently, four independent groups reported the presence of subclonal somatic mutations in the peripheral blood of individuals with no history of hematologic diseases (Genovese et al. 2014; Jaiswal et al. 2014; Xie et al. 2014; McKerrell et al. 2015).”
BackgroundInfluentialHow I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 182
“Clonally skewedhematopoiesis further complicatesPBanalysis, as;1% of healthy patients under 50 years of age and 10% of healthy patients over 65 years of age will accumulate mutations in genes associatedwithMDS/AL, several ofwhich causeHMMS if inherited in the germ line.(67,68) Thus, clinicians should avoid the use of…”
BackgroundGenetic basis and molecular profiling in myeloproliferative neoplasms
Luque Paz, D., Kralovics, R., & Skoda, R. C. (2023) · Blood · doi:10.1182/blood.2022017578 · Cited by 166
Clonal hematopoiesis and non-hematologic disorders
Jaiswal, S. (2020) · Blood · doi:10.1182/blood.2019000989 · Cited by 182
Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer
Adams, P. D., Jasper, H., & Rudolph, K. L. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.05.002 · Cited by 180
“…exponential increase in clonally expanded mutant stem cells in the male germline, the hematopoietic system, and the intestinal epithelium of aging humans (Busque et al., 2012; Genovese et al., 2014; Jaiswal et al., 2014; Greaves et al., 2006; Hsieh et al., 2013; Goriely and Wilkie, 2012).”
BackgroundInfluentialPredictors of mosaic chromosome Y loss and associations with mortality in the UK Biobank
Loftfield, E., Zhou, W., Graubard, B. I., Yeager, M., Chanock, S. J., Freedman, N. D., & Machiela, M. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-30759-1 · Cited by 178
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Morita, K., Kantarjian, H. M., Wang, F., Yan, Y., Bueso-Ramos, C., Sasaki, K., Issa, G. C., Wang, S., Jorgensen, J., Song, X., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6757 · Cited by 180
“TET2, and ASXL1—are often of preleukemic origin and the persistence of these mutations does not necessarily represent residual disease.(17-21) In contrast, a study by Klco and colleagues(22) demonstrated that the persistence of somatic mutations in remission was predictive of worse survival in AML.”
BackgroundGenetics of progression from MDS to secondary leukemia
Menssen, A. J., & Walter, M. J. (2020) · Blood · doi:10.1182/blood.2019000942 · Cited by 170
McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Chen, F., Ewing, J., Garg, M., Godfrey, A., S, S. K., McLornan, D. P., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15648 · Cited by 161
Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking
Dawoud, A. A. Z., Tapper, W. J., & Cross, N. C. P. (2020) · Leukemia · doi:10.1038/s41375-020-0896-8 · Cited by 181
Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression
Cargo, C. A., Rowbotham, N., Evans, P. A., Barrans, S. L., Bowen, D. T., Crouch, S., & Jack, A. S. (2015) · Blood · doi:10.1182/blood-2015-08-663237 · Cited by 178
Aging, Clonality, and Rejuvenation of Hematopoietic Stem Cells
Akunuru, S., & Geiger, H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.06.003 · Cited by 170
“Mutations in these genes have also been associated with MDS and AML [67,68].”
BackgroundInfluentialHolstein, S. A., Jung, S.-H., Richardson, P. G., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30140-0 · Cited by 173
Gale, D., Lawson, A. R. J., Howarth, K., Madi, M., Durham, B., Smalley, S., Calaway, J., Blais, S., Jones, G., Clark, J., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194630 · Cited by 172
Mechanisms that regulate the activities of TET proteins
Joshi, K., Liu, S., Breslin S.J., P., & Zhang, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04396-x · Cited by 162
Verger, E., Cassinat, B., Chauveau, A., Dosquet, C., Giraudier, S., Schlageter, M.-H., Ianotto, J.-C., Yassin, M. A., Al-Dewik, N., Carillo, S., et al. (2015) · Blood · doi:10.1182/blood-2015-07-659060 · Cited by 162
Fenaux, P., Haase, D., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.002 · Cited by 163
Vlasschaert, C., Mack, T., Heimlich, J. B., Niroula, A., Uddin, M. M., Weinstock, J. S., Sharber, B., Silver, A. J., Xu, Y., Savona, M. R., et al. (2023) · Blood · doi:10.1182/blood.2022018825 · Cited by 160
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 170
“The acquisition of further mutations drives the progression of CHIP to overt malignancy, as demonstrated by the common clonal origin of paired CHIP and AML samples.(31)”
BackgroundThe Loss of TET2 Promotes CD8+ T Cell Memory Differentiation
Carty, S. A., Gohil, M., Banks, L. B., Cotton, R. M., Johnson, M. E., Stelekati, E., Wells, A. D., Wherry, E. J., Koretzky, G. A., & Jordan, M. S. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700559 · Cited by 172
Genomic profiling for clinical decision making in lymphoid neoplasms
de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., et al. (2022) · Blood · doi:10.1182/blood.2022015854 · Cited by 169
NLRP3 inflammasome activation in inflammaging
Latz, E., & Duewell, P. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.09.001 · Cited by 174
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P., Haase, D., Sanz, G. F., Santini, V., & Buske, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu180 · Cited by 170
Increased somatic mutation burdens in normal human cells due to defective DNA polymerases
Robinson, P. S., Coorens, T. H. H., Palles, C., Mitchell, E., Abascal, F., Olafsson, S., Lee, B. C. H., Lawson, A. R. J., Lee-Six, H., Moore, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00930-y · Cited by 173
Emerging Principles in Myelopoiesis at Homeostasis and during Infection and Inflammation
Schultze, J. L., Mass, E., & Schlitzer, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.019 · Cited by 167
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M. A., Roboz, G. J., Gaidano, G., Scott, B. L., Greenberg, P., Platzbecker, U., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00009-7 · Cited by 169
Mack, P. C., Banks, K. C., Espenschied, C. R., Burich, R. A., Zill, O. A., Lee, C. E., Riess, J. W., Mortimer, S. A., Talasaz, A., Lanman, R. B., et al. (2020) · Cancer · doi:10.1002/cncr.32876 · Cited by 172
Mouhieddine, T. H., Sperling, A. S., Redd, R., Park, J., Leventhal, M., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16805-5 · Cited by 167
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
Tefferi, A., Vannucchi, A. M., & Barbui, T. (2024) · American Journal of Hematology · doi:10.1002/ajh.27216 · Cited by 194
“43,44”
Mullenders, J., Aranda-Orgilles, B., Lhoumaud, P., Keller, M., Pae, J., Wang, K., Kayembe, C., Rocha, P. P., Raviram, R., Gong, Y., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151323 · Cited by 163
“Recently, several studies have identified mutations in the originating stem cell in AML (Genovese et al., 2014).”
BackgroundFribbens, C., Garcia Murillas, I., Beaney, M., Hrebien, S., O’Leary, B., Kilburn, L., Howarth, K., Epstein, M., Green, E., Rosenfeld, N., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx483 · Cited by 168
“Clonal Haematopoesis of Indeterminate Potential (CHIP) is an age-related clonal expansion that is detectable in a high proportion of ageing people [15, 16].”
BackgroundJAK2V617F-Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure
Sano, S., Wang, Y., Yura, Y., Sano, M., Oshima, K., Yang, Y., Katanasaka, Y., Min, K.-D., Matsuura, S., Ravid, K., et al. (2019) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2019.05.013 · Cited by 170
“Analysis of the blood of transplanted mice established that this BMT led to the preferential expansion of mutant JAK2 hematopoietic cells to an extent that was comparable to the allelic fractions that are observed in individuals with clonal hematopoiesis (8,10,13).”
ResultClonal hematopoiesis is associated with protection from Alzheimer’s disease
Bouzid, H., Belk, J. A., Jan, M., Qi, Y., Sarnowski, C., Wirth, S., Ma, L., Chrostek, M. R., Ahmad, H., Nachun, D., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02397-2 · Cited by 169
Causes and consequences of clonal hematopoiesis
Weeks, L. D., & Ebert, B. L. (2023) · Blood · doi:10.1182/blood.2023022222 · Cited by 169
The potential of liquid biopsies for the early detection of cancer
Heitzer, E., Perakis, S., Geigl, J. B., & Speicher, M. R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0039-5 · Cited by 166
Aging, inflammation and cancer
Bottazzi, B., Riboli, E., & Mantovani, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.011 · Cited by 169
Cardiovascular Disease, Aging, and Clonal Hematopoiesis
Evans, M. A., Sano, S., & Walsh, K. (2020) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012419-032544 · Cited by 161
“Both of these studies observed that there was a marked increase in the frequency of hematological cancer in individuals with clonal hematopoiesis (13, 15), which is to be expected as mutations in driver genes represent an early step in the progression toward a hematological malignancy.”
BackgroundMethodResultInfluentialJensen, K., Konnick, E. Q., Schweizer, M. T., Sokolova, A. O., Grivas, P., Cheng, H. H., Klemfuss, N. M., Beightol, M., Yu, E. Y., Nelson, P. S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5161 · Cited by 167
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation
Gibson, C. J., Kim, H. T., Zhao, L., Murdock, H. M., Hambley, B., Ogata, A., Madero-Marroquin, R., Wang, S., Green, L., Fleharty, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02286 · Cited by 168
Evaluating measurable residual disease in acute myeloid leukemia
Ravandi, F., Walter, R. B., & Freeman, S. D. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016378 · Cited by 162
“However, the presence of AML-associated mutations may be indicative of early events in the development of hematologic malignancies in some cases because they significantly increase the risk of eventually developing one.(65,66) In a recent study, samples from 430 patients with AML in CR or CRi who had at least 1 mutati…”
BackgroundWang, Y., Sano, S., Yura, Y., Ke, Z., Sano, M., Oshima, K., Ogawa, H., Horitani, K., Min, K.-D., Miura-Yura, E., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.135204 · Cited by 167
“mutations that lead to subsequent clonal expansions (12, 13).”
BackgroundFemale chromosome X mosaicism is age-related and preferentially affects the inactivated X chromosome
Machiela, M. J., Zhou, W., Karlins, E., Sampson, J. N., Freedman, N. D., Yang, Q., Hicks, B., Dagnall, C., Hautman, C., Jacobs, K. B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11843 · Cited by 167
Advances in understanding of angioimmunoblastic T-cell lymphoma
Chiba, S., & Sakata-Yanagimoto, M. (2020) · Leukemia · doi:10.1038/s41375-020-0990-y · Cited by 161
Metadata
- Authors
- Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., Purcell, S. M., Svantesson, O., Landén, M., Höglund, M., Lehmann, S., Gabriel, S. B., Moran, J. L., Lander, E. S., Sullivan, P. F., Sklar, P., Grönberg, H., Hultman, C. M., & McCarroll, S. A.
- Affiliations
- Harvard University (US)
- Karolinska Institutet (SE)
- Science for Life Laboratory (SE)
- Stanley Center for Psychiatric Research (US)
- Memorial Sloan Kettering Cancer Center (US)
- Massachusetts General Hospital (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Gothenburg (SE)
- Uppsala University Hospital (SE)
- Karolinska University Hospital (SE)
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Genovese, Giulio
- Kähler, Anna K.
- Handsaker, Robert E.
- Lindberg, Johan
- Rose, Samuel A.
- Bakhoum, Samuel F.
- Mick, Eran
- Neale, Benjamin M.
- Fromer, Menachem
- Purcell, Shaun M.
- Landén, Mikael
- Höglund, Martin
- Lehmann, Sören
- Gabriel, Stacey B.
- Moran, Jennifer L.
- Lander, Eric S.
- Sullivan, Patrick F.
- Sklar, Pamela
- Grönberg, Henrik
- McCarroll, Steven A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-25
- Volume
- 371
- Issue
- 26
- Pages
- 2477-2487
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4290021
- OpenAlex
- W2126816979
- Cited by
- 3,531
- References
- 40
- Citations by year
- 2026: 240 · 2025: 293 · 2024: 315 · 2023: 363 · 2022: 386 · 2021: 360 · 2020: 356 · 2019: 310 · 2018: 294 · 2017: 254 · 2016: 215 · 2015: 134 · 2014: 6
- FWCI
- 143.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH077139, RC2MH089905)
- National Human Genome Research Institute (R01HG006855, U54HG003067, R01HG005827)
- National Cancer Institute (P30CA014051)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- clonal hematopoiesis, somatic mutations, DNMT3A, ASXL1, TET2, acute myeloid leukemia, early cancer detection, bone marrow biopsy, cancer susceptibility
- MeSH terms
- Adult, Age Factors, Aged, Aged, 80 and over, Blood, Cell Transformation, Neoplastic, Clone Cells, DNA Mutational Analysis, Hematopoiesis, Hematopoietic Stem Cells, Humans, Middle Aged, Mutation, Risk Factors, Hematologic Neoplasms, Young Adult, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.